Myeloid Cells & Cancer

Myeloid cells have many potent anti-cancer activities

Myeloid cells play a critical role in directing the immune responses. As first-responders they are the first immune cells on the scene of any immune challenge constantly recruited to cancer. On the scene they have an arsenal of weapons that can be deployed.  For example, myeloid cells directly kill cells, bacteria and viruses through a number of mechanisms including phagocytosis, cell-contact dependent killing and through the production of cell-toxic molecules. Myeloid cells assess the situations and will attract other immune cells including natural killer cells and T cells to the site as needed. Importantly, myeloid cells “prime” T cells, essentially arming T cells so they are able to respond to the challenge as well. This myeloid cell-based activation is essential for T cell activity. Taken together, myeloid cells can be considered the conductor of the immune system.

The ATAK™ platform harnessing these activities, results in an extremely versatile and potent cell therapy that may be applied to a number of disease conditions. Myeloid Therapeutics has developed a first in class approach to treating cancer by harnessing the innate abilities of myeloid cells to engulf cancer cells, produce anti-tumor agents, promote anti-tumor adaptive immunity and alter the tumor microenvironment, culminating in cancer death.

Rapidly recruited into cancers and other pathological conditions

Myeloid cells are a major white blood cell population in the circulating blood. Originating from stem cells in the bone marrow, they are constantly being delivered to the body via the circulation. Upon migration into tissues, myeloid cells can "mature” into numerous effector cell populations, which may have unique, tissue-dependent morphology and specific functions. For example, circulating myeloid cells are an important reservoir for many resident tissue cell populations. This includes liver Kupffer cells, bone osteoclasts, microglial cells in the brain as well as kidney mesangial macrophages and finally they may also differentiate into dendritic cells in lymphoid tissues and skin Langerhans cells. While myeloid cells are continuously supplied to most tissues, they are also recruited rapidly to sites of tissue injury or infection. In other words, myeloid cells are rapidly recruited to tissues where there is any change to the normal conditions.

Critically---Myeloid cells are also selectively and constantly recruited to cancer.

© 2020,   Myeloid Therapeutics.  All rights reserved.

  • LinkedIn
  • Instagram
  • Twitter

GET IN

TOUCH

300 Technology Square, Suite 203  Cambridge, MA 02139